Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs
Economic evaluation reveals substantial complication-related expenditures for diabetes in the UK, highlighting heavy future burdens under existing care regimes.
Key Points
Estimate current and future direct healthcare costs alongside indirect societal and productivity expenses for Type 1 and Type 2 diabetes in the UK.
Assessed economic burdens by evaluating direct health costs and indirect societal and productivity costs.
Analyzed resource impact to distinguish cost differences between Type 1 and Type 2 diabetes.
Projected future complication-related expenditures under current care regimes and rising disease prevalence.
Complications arising from Type 1 and Type 2 diabetes account for a substantial proportion of overall direct healthcare costs.
Economic costs required to treat disease complications are projected to increase substantially as prevalence grows unless existing care regimes are improved.